Evaluation of the effect of resveratrol isolated and in combination with tamoxifen on viability of breast cancer cells.

Breast cancer is treated with tamoxifen, an antagonist classified as selective estrogen receptor modulator, widely used for the first-line treatment of breast cancer. Resveratrol, a polyphenol present in the diet, has received attention due to its beneficial biological properties. There is great demand of science for new therapeutic targets for the treatment of breast cancer. Thus, evaluate cellular cytotoxicity of resveratrol, desmethyltamoxifen and their combination by the method MTT assay in culture estrogen-dependent breast cancer cells (MCF -7) and estrogen-independent (MDA-MB -231) will allow assess whether resveratrol provides benefits for the treatment of breast cancer. Our results indicate that the combination of resveratrol with tamoxifen reduced the viability of additive manner in breast cancer cells.